HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2024-11-23 (telanganatoday.com)
Telangana: Six pharma giants to invest Rs 5,260 cr in Pharma City
Under the agreements, MSN Laboratory will establish a manufacturing unit along with a Research & Development (R&D) center. Laurus Labs and Aurobindo Pharma will set up formulation units. Gland Pharma has shown interest in opening an R&D center, as well as manufacturing units for injectables and drug substances. Dr. Reddy's Labs plans to establish a unit for injectables and biosimilars. Hetero Labs will set up a plant for finished dose and injectable manufacturing.
Read more
2020-11-28 (newindianexpress.com)
Hyderabad-based Hetero Drugs to produce 100 million Sputnik V vaccine doses per year
HYDERABAD: Hyderabad-based pharmaceutical company Hetero Drugs has reached an agreement with the Russian Direct Investment Fund (RDIF) to produce over 100 milli
Read more
(thehindubusinessline.com)
Hetero plans to invest ₹1,000 crore over next 2 years in AP
40 per cent of global HIV drugs are manufactured in AP facility, says Vamsi Krishna Bandi, MD, Hetero
Read more
(fiercepharma.com)
Asia—GSK's India Zantac plant sale; Takeda-BridGene drug discovery pact; Celltrion's COVID antibody
GlaxoSmithKline is selling its Zantac plant in India for a fraction of its original investment in the wake of a global recall. | GlaxoSmithKline sold a Zantac plant in India to Hetero Labs in the wake of a global recall. Takeda penned a drug discovery pact with BridGene focused on neurodegenerative disease. Celltrion's COVID-19 antibody won backing from EMA's drug reviewers ahead of an official nod. And more.
Read more
(prnewswire.com)
RDIF and Morepen Laboratories announce production of the test batch of Sputnik V in India
/PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), and Morepen Laboratories, one of the leading manufacturers of...
Read more
(newsmeter.in)
Hyd-based Hetero Biopharma to produce 100 million doses of Sputnik V vaccine
The city-based pharma firm, Hetero Biopharma, in association with the Russian Direct Investment Fund (RDIF) will produce over 100 million doses per year of Sputnik V vaccine, the world’s first...
Read more
(business-standard.com)
Hetero sets up Russia venture
Hetero Drugs, the Hyderabad-based active pharmaceutical ingredients and finished dosages manufacturer, has set up an equal stakes joint venture with Russian pharmaceutical major Makiz Pharma.
Read more
(telanganatoday.com)
Hetero acquires manufacturing plant at Penjerla, to invest Rs 600 crore and create 2,000 jobs
Hyderabad: Hyderabad-headquartered pharma company Hetero said it acquired a manufacturing plant at Penjerla village of Kothur mandal in Mahbubnagar. The company committed an investment of about Rs.600 crore to upgrade and enhance the existing facilities at the site.
Read more
(economictimes.com)
Hetero acquires Johnson & Johnson's manufacturing plant in Telangana
"We are committed to an investment upwards of USD 75 million, (approximately Rs 600 crore) to upgrade and enhance existing facilities at the site and expand manufacturing of our global biologics and sterile pharmaceutical products," Hetero Managing Director Vamsi Krishna Bandi said.
Read more